Novo Nordisk shares jump 8% after Wegovy sales beat …
Nov 6, 2024 · Novo Nordisk added that sales of Wegovy were 79% higher year-on-year in the third quarter, coming in at 17.3 billion Danish kroner. ... The news was taken as a signal that …
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, …
6 days ago · COPENHAGEN, Nov 6 (Reuters) - Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors …
Novo Nordisk CEO on Wegovy prices, supplies and compounding
LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its …
News Details - Novo Nordisk
Mar 8, 2024 · Wegovy®, a semaglutide-based therapy for weight management, has received US FDA approval to reduce the risk of major adverse cardiovascular events in people with …
News details - Novo Nordisk
PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® to …
News Details - Novo Nordisk
Bagsværd, Denmark, 25 July 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has …
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) …
News details - Novo Nordisk
Nov 11, 2023 · Novo Nordisk has filed for a label update of Wegovy ® in the US and EU to include an indication for reducing the risk of major adverse cardiovascular events …
News Details - Novo Nordisk
Nov 11, 2021 · Wegovy™ is a once-weekly semaglutide 2.4 mg injection that reduces hunger and increases fullness for chronic weight management in adults with obesity or overweight. The …
Novo Nordisk’s Wegovy sales jump on international rollouts
Nov 6, 2024 · Novo Nordisk’s 11% 3Q beat for obesity drug Wegovy and reiterated guidance should assuage some concerns about GLP-1 market dynamics following a weak 3Q from …
- Some results have been removed